1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002; 35:5 Suppl 2. S72–S78.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004; 127:5 Suppl 1. S27–S34.
3. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology. 2004; 127:5 Suppl 1. S133–S143.
4. Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009; 192:1675–1681.
5. Kwak HS, Lee JM, Kim YK, Lee YH, Kim CS. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol. 2005; 15:140–147.
6. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H. Magnetic resonance imaging of hepatocellular carcinoma. Oncology. 2008; 75:Suppl 1. 65–71.
7. Kim MJ, Choi JY, Chung YE, Choi SY. Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology. 2008; 75:Suppl 1. 72–82.
8. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008; 247:311–330.
9. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol. 2007; 17:2519–2530.
10. Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009; 193:1053–1060.
11. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008; 18:457–467.
12. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology. 2005; 234:468–478.
13. Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tombach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199:177–183.
14. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010; 255:459–466.
15. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology. 2006; 239:122–130.
16. Hollingsworth KG, Lomas DJ. Influence of perfusion on hepatic MR diffusion measurement. NMR Biomed. 2006; 19:231–235.
17. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188:1622–1635.
18. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010; 254:47–66.
19. Choi JY, Kim MJ, Chung YE, Kim JY, Jones AC, de Becker J, et al. Abdominal applications of 3.0-T MR imaging: comparative review versus a 1.5-T system. Radiographics. 2008; 28:e30.
20. Merkle EM, Dale BM, Paulson EK. Abdominal MR imaging at 3T. Magn Reson Imaging Clin N Am. 2006; 14:17–26.
21. Soher BJ, Dale BM, Merkle EM. A review of MR physics: 3T versus 1.5T. Magn Reson Imaging Clin N Am. 2007; 15:277–290. v
22. Choi SH, Lee JM, Yu NC, Suh KS, Jang JJ, Kim SH, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol. 2008; 191:529–536.
23. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011; 55:126–132.
24. Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology. 1997; 204:739–744.
25. Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology. 2008; 246:812–822.
26. Zech CJ, Herrmann KA, Dietrich O, Horger W, Reiser MF, Schoenberg SO. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol. 2008; 43:261–266.
27. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol. 2009; 193:438–444.
28. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. The efficacy of diffusion-weighted imaging for the detection of colorectal cancer. Hepatogastroenterology. 2009; 56:128–132.
29. Xu PJ, Yan FH, Wang JH, Lin J, Ji Y. Added value of breath-hold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging. 2009; 29:341–349.
30. Holzapfel K, Bruegel M, Eiber M, Ganter C, Schuster T, Heinrich P, et al. Characterization of small (≤10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol. 2010; 76:89–95.
31. Nishie A, Tajima T, Ishigami K, Ushijima Y, Okamoto D, Hirakawa M, et al. Detection of hepatocellular carcinoma (HCC) using super paramagnetic iron oxide (SPIO)-enhanced MRI: Added value of diffusion-weighted imaging (DWI). J Magn Reson Imaging. 2010; 31:373–382.
32. Hardie AD, Naik M, Hecht EM, Chandarana H, Mannelli L, Babb JS, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol. 2010; 20:1431–1441.
33. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988; 168:497–505.
34. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging. 2008; 27:834–839.
35. Kim YK, Kim CS, Han YM, Lee YH. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol. 2011; 66:489–496.
36. Choi JY, Choi JS, Kim MJ, Lim JS, Park MS, Kim JH, et al. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent. J Magn Reson Imaging. 2010; 31:571–578.
37. Kim YK, Ko SW, Hwang SB, Kim CS, Yu HC. Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur Radiol. 2006; 16:1337–1345.
38. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol. 2004; 14:5–13.
39. Wang H, Wang XY, Jiang XX, Ye ZX. Comparison of diffusion-weighted with T2-weighted Imaging for detection of small hepatocellular carcinoma in cirrhosis: preliminary quantitative study at 3-T. Acad Radiol. 2010; 17:239–243.